Multicenter community-based trial of Amlodipine in hypertension

C. Yosefy, J. R. Viskoper, Y. Leshem, Y. Rav-Hon, G. I. Rosenberg, E. Yaskil

Research output: Contribution to journalArticlepeer-review


The safety and efficacy of Amlodipine (AML) for mild to moderate hypertension was evaluated in a 'real life' setting. This open non- comparative trial included 123 men and 143 women (age 30-91 years, mean 59.4). All had sitting diastolic blood pressure (DBP) between 95 and 115 mmHg, confirmed in most by 2 baseline measurements, 2 weeks apart. Eligible patients were given AML 5 mg daily as add-on or monotherapy and were evaluated 4 weeks later. If DBP was then > 90 mmHg, the daily dose was raised to 10 mg; those with < 90 mmHg remained on 5 mg. AML was continued for 8 weeks. Other BP-lowering drugs were unchanged. Of the original 266 patients 22 (8.2%) withdrew due to adverse events (AE), and others were protocol violators, lost to follow-up or withdrew, leaving 211 available for efficacy analysis. In this major group BP was reduced from 165±15/101±4 to 139±11/83±5 after 12 weeks of AML (p < 0.05). The reduction was greater in those under 70 years, from 173±12/100±5 to 142±12/80±4 (p < 0.05). In those with BMI > 30 kg/m2, BP decreased from 165±15/101±5 to 140±12/83±5 (p < 0.05). Mean change in heart rate was -1.5 bpm (p < 0.05). Mean final AML dose was 5.5 mg/day. The most common AML-related AE requiring cessation of the drug was pedal edema in 2.6% of the 266 patients; in 3.7% it persisted during therapy. Other AE occurring in > 1% were dizziness in 1.8%, headache 1.5%, flushing 1.1% and fatigue 1.1%. We conclude that AML is an effective and well-tolerated antihypertensive suitable for most hypertensive patients.

Original languageEnglish
Pages (from-to)89-93+176
Issue number3-4
StatePublished - 1 Aug 1999


  • Amlodipine
  • Blood pressure
  • Calcium blocker
  • Community
  • Hypertension


Dive into the research topics of 'Multicenter community-based trial of Amlodipine in hypertension'. Together they form a unique fingerprint.

Cite this